By a News Reporter-Staff News Editor at Life Science Weekly -- Data detailed on Nanoparticles have been presented. According to news reporting from Vitoria, Spain, by NewsRx journalists, research stated, "Self-amplifying RNA or RNA replicon is a form of nucleic acid-based vaccine derived from either positive-strand or negative-strand RNA viruses. The gene sequences encoding structural proteins in these RNA viruses are replaced by mRNA encoding antigens of interest as well as by RNA polymerase for replication and transcription."
The news correspondents obtained a quote from the research from the University of Basque Country, "This kind of vaccine has been successfully assayed with many different antigens as vaccines candidates, and has been shown to be potent in several animal species, including mice, nonhuman primates, and humans. A key challenge to realizing the broad potential of self-amplifying vaccines is the need for safe and effective delivery methods. Ideally, an RNA nanocarrier should provide protection from blood nucleases and extended blood circulation, which ultimately would increase the possibility of reaching the target tissue. The delivery system must then be internalized by the target cell and, upon receptor-mediated endocytosis, must be able to escape from the endosomal compartment into the cell cytoplasm, where the RNA machinery is located, while avoiding degradation by lysosomal enzymes. Further, delivery systems for systemic administration ought to be well tolerated upon administration. They should be safe, enabling the multiadministration treatment modalities required for improved clinical outcomes and, from a developmental point of view, production of large batches with reproducible specifications is also desirable."
According to the news reporters, the research concluded: "In this review, the concept of self-amplifying RNA vaccines and the most promising lipid-based delivery systems are discussed."
For more information on this research see: Development of nucleic acid vaccines: use of self-amplifying RNA in lipid nanoparticles. International Journal of Nanomedicine, 2014;9():1833-1843. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Nanoparticles).
Our news journalists report that additional information may be obtained by contacting A. Rodriguez-Gascon, Univ Basque Country UPV EHU, Center Invest Lascaray Ikergunea, Fac Pharm, Pharmacokinet Nanotechnol & Gene Therapy Grp Phar, Vitoria, Spain. Additional authors for this research include A. del Pozo-Rodriguez and M.A. Solinis.
Keywords for this news article include: Antigens, Spain, Europe, Vitoria, Immunology, Nanotechnology, Biological Factors, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC